Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

LUDWIG Heinz ADAM Zdeněk TOTHOVÁ Elena HÁJEK Roman LABAR Boris EGYWD Miklós ŠPIČKA Ivan GISSLINGER Heinz DRACH Johannes KUHN Ingrid HINKE Axel ZOJER Niklas

Year of publication 2010
Type Article in Periodical
Magazine / Source Haematologica
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords thalidomide; multiple myeloma; thalidomide-interferon; progression free survival
Description Thalidomide maintenance therapy after stem cell transplantation resulted in increased progression-free survival and overall survival in a few trials, but its role in non-transplant eligible patients with multiple myeloma remains unclear. This study assessed the impact of thalidomide-interferon in comparison to interferon maintenance therapy in elderly patients with multiple myeloma.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.